Skip to main
ICLR

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 21%
Sell 7%
Strong Sell 0%

Bulls say

Icon is expected to see a temporary delay in their share buybacks but has shown strong performance in win rates and bookings. Meanwhile, their competitor ICLR is facing margin declines but has implemented steps to address the issue and invest in growth opportunities, including a technology partnership and divestment. Both companies are confident in their future success, although risks from emerging technologies remain a potential concern.

Bears say

Icon is facing potential risks, including the possibility of further accounting reviews or restatements which could impact investor confidence and future revenue. Additionally, the company's success may be impacted if it is unable to deliver clinical trials on time or secure sensitive clinical trial data. However, there is potential for upside in the stock due to Icon's strong partnerships with large pharmaceutical companies, stabilizing biopharma funding, and favorable clinical trial trends pointing to increased demand for CRO services. While management has indicated positive net bookings trends, there may still be some concerns about the potential impact of AI on the industry. Overall, the stock is currently trading at a fair value, and we rate it as Hold.

ICON (ICLR) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 21% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 14 analysts, ICON (ICLR) has a Buy consensus rating as of Jul 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $184.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $184.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.